BridgeBio Pharma Reports Q4 Loss, Revenue Exceeds Estimates
PALO ALTO, Calif. - BridgeBio Pharma Inc. (BBIO) announced a loss of $265.1 million in its fourth quarter, with a per-share loss of $1.40. Adjusted for non-recurring costs, the loss was $1.31 per share, falling short of analysts' expectations.
Analysts from Zacks Investment Research had forecast a loss of $1.09 per share. Revenue for the quarter reached $5.9 million, surpassing market projections. Five analysts surveyed by Zacks expected $5.3 million.
For the full year, the company's loss narrowed to $535.8 million, or $2.88 per share. Revenue totaled $221.9 million.
BridgeBio Pharma shares have performed positively since the beginning of the year, rising by 32%. In the past 12 months, the stock has gained nearly 1%.